Testing the eukaryotic promoters for efficient expression of exogenous genes in chondrocytes and synoviocytes  by Su, Suming et al.
FEBS 17643 FEBS Letters 395 (1996) 179 182 
Testing the eukaryotic promoters for efficient expression of exogenous 
genes in chondrocytes and synoviocytes 
Suming Su a, Lashitew Gedamu c, Faramaze Dehnade b, Muhammad Zafarullah a,* 
aDdpartement de Mddecine, Universitk de Montrdal and Centre de Recherche Louis-Charles Simard, H6pital Notre-Dame, 1560 Sherbrooke st, 
Montreal, Quebec H2L 4M1, Canada 
bDdpartement de Chirurgie Orthopkdique, Universitk de Montrkal and Centre de Recherche Louis-Charles Simard, H6pital Notre-Dame, 
1560 Sherbrooke st Montrkal, Montrkal, Qukbec H2L 4M1, Canada 
~Biologieal Sciences, University of Calgary, Calgary, Alberta T2N 1N4, Canada 
Received 2 September 1996 
therapy research for joints has been very slow. The prospects Abstract To identify suitable promoters for expressing exog- 
enous genes in arthritic joints, the constitutive, simian virus 40 for such treatment were proposed recently by Bandara et al. 
(SV 40) and IL-I or metal inducible, human stromelysin and [4]. It was suggested that joints are poor targets of conven- 
metallothionein (MT) gene promoters were tested for their tional drugs administered by intravenous, oral and intramus- 
activity in chondrocytes and synovial fibroblasts. Transient cular means. The intra-articularly injected drugs have a short 
transfection with plasmids containing the reporter chloramphe- half-life. Two approaches for treating arthritis with genes were 
nicol acetyltransferase (CAT) gene attached to these promoters proposed. The antiarthritic genes could be introduced irectly 
showed that SV40, stromelysin and MT promoters drove CAT in synoviocytes by means of the viral vectors. Alternatively, 
expression with different strengths in primary bovine chondro- synovium could be removed, synoviocytes grown in culture, 
cytes. The MTI-F and MT-IG gene promoters were also genetically modified and transplanted back into synovium. 
functional in human chondrocytes. The SV40, IL-1 inducible The second approach was utilized to introduce E. coli mar- 
stromelysin-1 and MT-IG driven CAT activity was also 
detectable in human synoviocytes. Therefore, choudrocytes and kers; an easily assayable [3-galactosidase (lacZ) and neomycin 
synoviocytes have the trans-acting factors necessary for tran- antibiotic resistance genes. These lacZ + cells persisted in joints 
scription from the respective promoters which may be conserved for 3 months. Attempts at direct gene transfer into synovium 
in bovine and human cells. These promoters could be useful for did not succeed as retroviral vectors need dividing cells to 
expressing potentially therapeutic anti-inflammatory and anti- transduce their DNA [4]. These investigators ubsequently 
erosive genes in arthritic joints, reported retrovirus-mediated ex vivo transduction of the mar- 
kers and interleukin 1-receptor antagonist protein (IRAP) into 
Key words." Chondrocyte; Osteoarthritis; Promoter; rabbit synoviocytes which after reinjection colonized the sy- 
Synoviocyte; Transfection novium and expressed elevated levels of biologically active 
IRAP for 5 weeks. After recombinant IL-I[~ injection, the 
knee joints expressing IRAP, were protected from the leukosis 
1. Introduction [5]. The knees of control rabbits developed leukocyte infiltra- 
tion in the joint space, synovial thickening, hypercellularity 
Osteoarthritic (OA) is a common disorder of joints with and loss of proteoglycans from cartilage. These symptoms 
unknown etiology. Factors such as joint overuse, injuries, were inhibited by IRAP [6]. This important study demon- 
obesity, aging, hormones (more women affected), life-style strated the potential of gene therapy for arthritis. 
and mutations in the cartilage-specific type II collagen gene Arthritis is a complex multi-factorial group of diseases and 
in heritable forms of the disease have been implicated in OA these authors have noted that the only anti-inflammatory 
[1]. A related but more aggressive disease, rheumatoid arthri- IRAP may not have all the antiarthritic properties. In another 
tis (RA), has more auto-immunological etiology and much report, the lacZ gene under the control of cytomegalovirus 
pronounced synovial inflammation and hyperplasia [2]. A early promoter placed in an adenovirus vector was directly 
common manifestation of RA and OA is the progressive injected in rabbit joints. The expression and high efficiency 
loss of articular cartilage and release of extracellular matrix transfer was demonstrated by in situ [~-galactosidase (produc- 
(ECM) components in synovial fluid and plasma by activated tion of blue color), immunohistochemical staining and elec- 
matrix metalloproteinases (MMPs) [3]. This leads to exposure tron microscopy in type A and B synoviocytes. Expression 
of underlying bone and disability. Currently, these diseases lasted for 8 weeks after infection [7]. In a recent study, cells 
are treated with non-steroidal anti-inflammatory drugs transfected with an anti-inflammatory c tokine, IL-4 cDNA, 
(NSAIDs), steroids, gold compounds, methotrexate and by over-produced this protein and upon injection in mice, re- 
surgical means with limited success. With a better understand- sulted in some improvement in collagen induced arthritis com- 
ing of the molecular mechanisms of the diseases, a recent pared to joints with non-transfected cells [8]. All the cited 
alternative to conventional therapy is to target the genes in- studies have targeted the inflammatory aspect of arthritis. 
volved in the disease either by blocking them with antisense However, there is a clear need to target other aspects uch 
nucleic acids or by overexpression f poorly expressed or de- as the degradation of cartilage by metalloproteinases originat- 
fective genes, ing from synoviocytes, inflammatory cells and chondrocytes. 
Compared to the diseases of other organs, progress in gene In addition, techniques of gene therapy can in principal be 
applied to inhibit undesirable gene products and to stimulate 
*Corresponding author. Fax: (1) (514) 876-6630. repair processes. Basic research is needed to test the efficiency 
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of different eukaryotic promoters, and to develop methods % ACETYLATION 
and vectors for DNA delivery in matrix-rich tissues like car- 
O.O NO ENZYME 
tilage. The proper choice of promoters is an important factor 
for successful therapeutic gene transfer and efficient expres- o.o NO DNA (MOCK) 
sion of the exogenous genes. This study was aimed at testing v _ ,  
functionality of human metallothionein, stromelysin and 48.06 ~e ~e ~i O the )CAT CONTROL 
simian virus 40 promoters in chondrocytes and synoviocytes. 
51.56 e e ~ O  )CAT CONTROL +IL-IB 
2. Materials and methods 51.98 e4P • pCAT CONTROL + Znel, 
2.1. Chondrocyte and synovial fibroblast culture 0.66 e pCAT BASIC 
Human cartilage and synovium were obtained immediately after 
total knee or hip replacement surgery of patients with OA. Bovine 0.64 • pCAT BASIC + IL-1 a- 
articular cartilage was obtained from the femoral heads, condyles and 
tibial plateaus of freshly slaughtered normal adult animals through a 0.64 e pCAT BASIC + ZnCt~ 
local slaughterhouse. The cartilage-containing bones were dipped 
briefly in 1% proviodine (Rougier Inc., Chambly Quebec) for sterili- 12.17 ~ l STL-1303 to +4 CONTROL 
zation and washed extensively with 0.9% NaC1. The slices of cartilage 
were dissected out, kept for 1-2 h at 4°C in 5 × antibiotic-antimycotic 26.23 ~ STL-1303 to +4 IL-1K 
solution and washed five times with large volumes of phosphate-buf- 
fered saline (PBS) containing 5× penicillin-streptomycin and 1 X fun- 2.17 O ~ hMT-IF-CAT CONTROL 
gizone (Gibco-BRL Burlington, Ontario). Chondrocytes were released 
from cartilage following digestion with pronase (1 mg/ml) for 90 min 2.97 ~e ~ hMT-IF-CAT + ZnCl 2 
and clostridial collagenase (Sigma type II) for 12 h in DMEM alone 
t or supplemented with 10% fetal calf serum (Gibco BRL) at 37°C. 9.20 e hMT-IG CAT CONTROL 
Viability was about 80% as determined by trypan blue exclusion 
e | test. For primary cultures, cells were passed through a sterile micro- 10.20 hMT-IO CAT + ZnCl 2 
sieve to remove debris. The cells were pelleted at 2000 rpm for 15 min 
and washed three times with PBS and plated at high density. The cells Fig. 1. Transfection of primary bovine chondrocytes with SV40, 
were first allowed to attach to the plates in DMEM alone for 4 h [9] stromelysin and metallothionein promoters. CAT assay of protein 
and then supplemented with 10% serum for confluent growth (up to 3 extracts (20 Hg) normalized with the SV40-driven I~-galactosidase ac- 
days). Synovial membranes were dissociated with trypsin for 1 h and tivities from primary bovine chondrocytes transfected transiently 
with collagenase for 6 h and adherent fibroblast-enriched cultures with CaPO4 precipitate only (no DNA), 20 ~tg of a vector with 
selected after several passages. CAT under the SV40 early promoter (pCAT control), a vector with 
CAT but without a promoter (pCAT basic), human stromelysin-1 
2.2. Plasmids, transient ransfection and CAT assay (STL) promoter ( 1303 to +4) in pGCAT-C and human MT-IG 
The three well characterized human MT gene promoter vectors and MT-IF-CAT vectors. The inductions were performed 60 h post- 
named p630 MT-IG-CAT, p437 MT-IF-CAT [10] and hMT-IIA transfection to permit cell recovery. IL-I (20 ng/ml) and ZnC12 (100 
CAT [11] cloned upstream of the bacterial CAT gene in pGEM-2 ktM) treatment was for 24 h in serum-free medium or 8 h in serum- 
(Promega) based vector were utilized. The MT-IG-CAT contains nu- containing medium, respectively. The film was exposed for 24 h. 
cleotides -630 to +65 of the gene and includes a TATAAA motif and The 'no enzyme' lane contains all the assay reagents but no protein 
four metal responsive lements (MREs). The MT-IF-CAT contains extract. 
sequences 437 to +71 comprising a TATCA box, four MREs and 
several SP-1 binding sites. The hMT-IIA (-770 to +75) promoter 
contains a positive glucocorticoid responsive lement (GRE) besides speed vac and resuspended in 30 lal of ethyl acetate. The acetylated 
MREs and is therefore inducible by both metal salts and dexametha- forms of Cm were separated by ascending thin-layer chromatography. 
sone in the human hepatoma (HepG2) cell line [11]. The pCAT Basic Autoradiography was performed to detect CAT activity by localizing 
(Promega) plasmid has no promoter cloned upstream of the CAT different forms of Cm and percent acetylation determined by scintilla- 
gene. The pCAT control vector has CAT gene under the control of tion counting of the spots. 
the SV 40 promoter. The vector p+4CAT contained CAT gene under 
the control of the human stromelysin-1 1303 to +4 promoter region 2.3. lS-Galactosidase assay 
[12]. This fragment has 480 base pairs of 5' region which has most of Along with the test plasmids, 10 lag of pSV-fl-galactosidase control 
the elements responsible for induction by interleukin-1 and phorbol vector (Promega Corp.) was co-transfected in bovine chondrocytes 
esters. However, the sequences upstream from 480 were recently and human synoviocytes. 20 ktg of protein extract was assayed for 
found to be rearranged in this construct and an additional 1 kb frag- ~-galactosidase enzyme with the assay system of Promega according 
ment was characterized [13]. The role of this 1 kb segment in regula- to their instructions [16]. The extract was incubated for 30 min with 
tion of this gene is not known, reaction buffer containing o-nitrophenyl-13-D-galactopyranoside as 
For transfections, cells were plated at a density of 100 000 per 35 substrate, the reaction terminated with sodium bicarbonate and the 
mm (or in 6-well plates for human cells) plate. Prior to transfection, absorbance of the yellow colored o-nitrophenol measured at 420 nm 
cells were given fresh medium. Plasmids (20 lag) were isolated by with a spectrophotometer. 
Qiagen column purification and precipitated (500 lal) using the cal- 
cium phosphate method [14] and added to the plates. After 4 h of 
transfection, the medium was removed, washed once with PBS and 3. Results 
cells glycerol (15%) shocked for 1 min, washed and incubated with 
medium for 24 h. Cells were then treated with interleukin-l~ (20 ng/ 
ml) for 24 h or zinc chloride for 8 h and collected by scraping, and To test the functionality of different eukaryotic promoters 
lysed in 200 lal of 0.25 M Tris-HC1 (pH 7.8) by sonication. The in bovine and human chondrocytes and synoviocytes, plasmid 
protein content of the lysate was measured by the Bradford method constructs with the bacterial chloramphenicol acetyl transfer- 
using Bio-Rad reagents [15]. CAT assay were performed by adjusting ase (CAT) gene placed downstream of different eukaryotic 
20 ~tg of protein extract o 120 ktl with Tris, combined with 20 ~tl of 
[a4C]chloramphenicol (Cm) (0.133 laCi) (Dupont-NEN Canada) and promoters were obtained or constructed (see Section 2). For 
20 ~tl of 4 mM acetyl-CoA (0.5 mM final). After 8 h incubation at monitor ing transfection efficiencies, cells were co-transfected 
37°C, Cm was extracted with ethyl acetate, solvent evaporated by with a vector expressing 13-galactosidase enzyme under SV 40 
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promoter. Transient ransfection by the calcium phosphate % ACETYLATION 
precipitation method into the primary monolayer cultures of .... :i:~ NO ENZYME 
bovine chondrocytes and CAT assay normalized with 13-galac- o.oo ..... ,~ 
tosidase activity revealed that the SV 40 early promoter was o.oo NO DNA (MOCK) 
unresponsive to ZnCl2 or IL-1 but was most active constitu- 21.a4 ,CAT CONTROL 
tively in these cells. The promoterless vector alone or with 
inducing agents had negligible CAT activity. The stromely- 29.28 ,CAT CONTROL + IL-I~ 
sin-1 promoter was clearly able to drive the expression of 26.93 )CAT CONTROL + ZnClz 
the CAT gene at basal level whose activity was approx. 2- o.38 ,CAT BASIC 
fold inducible with interleukin-l[3. MT-IF and MT-IG trans- 0.35 )CAT BASIC + IL-lg 
fected cells had considerable basal CAT activity which was 
higher for the latter promoter. MT-IG promoter was 34-  0.42 )CAT BASle + ZnCI= 
fold stronger than MT-IF. Induction with Zn in both cases 9.40 STL-1303to +4CONTROL 
.... STL -1303 to +4 IL-1S wa no wr o vious , ,  i 
The metal (Cd, Zn) inducible, metallothionein promoters ..... hMT-IF-CAT CONTROL 
have been a popular choice in numerous transgene expressions 1.4o hMT-IF-CAT + ZnCl= 
!!)iiiiiil  and stable transfections of foreign genes [17,18]. Transient 1.~ hMT-IG CAT CONTROL 
hMT-iG CAT + ZnCi z transfection of these vectors in human OA chondrocytes 4.88 
and CAT assay depicted in Fig. 2 revealed that MT-IG pro- 
moteT was functional at basal levels and could be induced to 5.5s .... 
slightly higher levels by metal salt treatment. In Zn-treated Fig. 3. Demonstration f SV40, human stromelysin and metallothio- 
cells, MT-IG promoter appeared to be stronger than MT-IF nein IG and F promoter driven CAT activity in human synovial fi- 
while MT-IIA was inactive in three experiments (results not broblasts. The CAT assays with 20 lag of protein extract (normal- 
ized with the SV40-driven 13-galactosidase ctivity) show successful 
shown). Other controls such as MT-IF-CAT (uninduced) transfection and activity of SV40 (pCAT control) and MT promo- 
could not be tested due to the limited availability of human ters. The inducibility of the stromelysin promoter with IL-1 is also 
OA chondrocytes, shown. Conditions were the same as in Fig. 1. Time of autoradiog- 
In synovial fibroblasts, the promoterless vectors alone or raphy was 24 h. 
with inducing agents had very little CAT activity (Fig. 3). 
As in bovine chondrocytes, the constitutive SV 40 promoter 
was the most active promoter in human synovial fibroblasts, tested some eukaryotic promoters and demonstrated their ac- 
followed by stromelysin, MT-IG and MT-IF; the latter being tivity in human and bovine connective tissue cells. The bovine 
the weakest. The MT-IG and MT-IF promoters were also cartilage x vivo model system, because of its abundant avail- 
functional at the basal evel but could not be induced further ability, is a widely used and well-recognized system in ortho- 
with ZnC12 as evident from the ~-galactosidase normalized paedic and cartilage matrix research. 
CAT activity depicted as percent acetylation ormalized The activity of SV40, stromelysin and MT promoters in 
with I~-galactosidase activity. The MT-IG promoter had 3- bovine chondrocytes demonstrated that cis-acting factors of 
times higher activity than MT-IF. The basal stromelysin pro- these promoters are recognized by the bovine transcription 
moter activity could be induced 1.6-fold by interleukin-ll3 factors. These may include AP-1 (fos/jun) and PEA-3 factors 
treatment in these cells (Fig. 3). which are responsible in part for regulation of the stromelysin 
gene by phorbol esters in human cells [20]. The 480 base pairs 
4. Discussion in the 1.3 kb promoter segment most likely contain all the 
sequences necessary for promoter activity in bovine cells. 
The utilization of appropriate promoters is an important This conservation is also extended to the protein-coding 
factor for successful therapeutic gene transfer and its high- part of the gene where human stromelysin probes cross-hy- 
level expression in target tissue [19]. In this report, we have bridize with corresponding bovine mRNA (our unpublished 
results). 
% ACETYLATION The activity of metallothionein promoters in bovine and 
human chondrocytes i  consistent with our earlier observa- 
0.02 I . . . .  NO ENZYME tions that the MT genes are expressed in bovine [21] and hu- 
0.03 1 ~ . . . . . .  NO DNA (MOCK) man [22] chondrocytes, and on these grounds, the respective 
~i ~ promoters are likely to function in in vivo gene transfer ex- 
10.50 i hMT-IG-CAT CONTROL periments. MT regulatory factors are therefore present in car- 
12.74 : hMT-IG-CAT + ZnCl2 tilage and to a lesser extent in synovium [23]. The higher 
activity of MT-IG over MT-IF promoter in chondrocytes 
6.50 " ,  ~ hMT-IF-CAT + z.c,,  and synoviocytes may be related to the presence of a canoni- 
Fig. 2. Activity of human metallothionein IG and F promoters in cal TATAAA in the former and an altered TATCAA in the 
human chondrocytes. Autoradiogram of CAT assay of protein ex- latter promoter which were in part responsible for differential 
tract from human OA chondrocytes (l t passage) transfected with a expression of these genes in HepG2 cells [24]. Surprisingly, 
vector where human metallothionein-IG and F promoters are fused hMT-IIA, the strongest of all the human MT promoters in 
with the bacterial CAT gene. The cells were either untreated or 
treated with 100 ~tM ZnC12 for 7 h in the presence of 10% serum other cell types, was not active in our cells, suggesting a lack 
after transfection. Other denotations as in Fig. 1. Time of film ex- of certain regulatory factors specific to this gene. Of the three 
posure was 48 h. MT promoters tested so far, the MT-IG promoter seemed to 
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